Articles On Kazia Therapeutics (ASX:KZA)

Title Source Codes Date
Kazia says diversification is the key to drug development

Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas. The company currently has eight c...

Stockhead KZA 17 hours ago
Evening Report: 8 August, 2022

ShareCafeEvening Report: 8 August, 2022 by Paul Sanger   After falling early in the session, the ASX managed to close in the green. Lithium stocks led the way, following comments from Albemarle that the lithium supply will remain tight for...

ShareCafe KZA 1 week ago
Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP & Oz Minerals

08 Aug 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Mesoblast (ASX:MSB), BHP Group (ASX:BHP) and Oz Minerals (ASX:OZL).

FNN KZA 1 week ago
Lunch Report: 8 August, 2022

ShareCafeLunch Report: 8 August, 2022 by Paul Sanger   On the ASX this week we kick off the earnings season with 17 major ASX 200 companies reporting, including Suncorp (ASX:SUN) (today and more on its proposed bank sale to the ANZ), Comput...

ShareCafe KZA 1 week ago
Stocks of the Hour: 8 August, 2022

ShareCafeStocks of the Hour: 8 August, 2022                    Kazia Therapeutics Limited (ASX:KZA) an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase 1 cl...

ShareCafe KZA 1 week ago
ASX Health Stocks: Acrux and Lumos await potential approvals from the US FDA

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

Stockhead KZA 1 week ago
Australian Broker Call *Extra* Edition – Aug 08, 2022

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

FNArena KZA 1 week ago
Kazia Therapeutics (ASX:KZA) delivers “promising” initial data from brain metastases trial

Kazia Therapeutics (KZA) presents “promising” new data from an ongoing phase I clinical trial of its paxalisib product for the treatment of brain metastases The trial treated nine patients with paxalisib in combination with radiotherapy, w...

themarketherald.com.au KZA 1 week ago
Kazia Therapeutics reveals 100% response rate in interim data from brain metastases drug trial

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Inter...

SmallCaps KZA 1 week ago
Market highlights and 5 ASX small caps to watch on Monday

The ASX 200 will open slightly lower on Monday US non-farm payrolls surprise on the upside, but Wall Street finishes mixed on Friday Ahead this week, earnings season starts for ASX blue chips Local shares are set to open lower today. At 8...

Stockhead KZA 1 week ago
The Week that Was – August 1-5, 2022

ShareCafeThe Week that Was – August 1-5, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, h...

ShareCafe KZA 1 week ago
Lunch Report: 5 August, 2022

ShareCafeLunch Report: 5 August, 2022 by Tim McGowen   Gold stocks are stronger across the board as the price of gold reaches one month highs as the $US weakens and geopolitical tensions rise with China & Taiwan. The annual Diggers &amp...

ShareCafe KZA 1 week ago
Global Biotech Turnaround Looks to Be Underway

ShareCafeGlobal Biotech Turnaround Looks to Be Underway Signs of life are emerging in the global biotech sector, after the longest and sharpest downturn in history that was so severe it left hundreds US companies trading below cash backing....

ShareCafe KZA 1 week ago
Kazia: AGILE Hurdle Missed but Significant Value Remains

ShareCafeKazia: AGILE Hurdle Missed but Significant Value Remains Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download...

ShareCafe KZA 1 week ago
Closing Bell: We all forgot to buy Cobre stock last Monday, but don’t worry, it’s only up 360%

The ASX 200 is up 0.6%, the XEC small caps index is down 0.8%  Tomorrow is RBA day, Wednesday is OPEC+ arvo We all should’ve bought into CBE last week, dammit    The local sharemarket is creeping quietly higher on Wednesday, with the reso...

Stockhead KZA 2 weeks ago
This ASX healthcare share just crashed 49%, here’s why

In case you were wondering, it is the Kazia Therapeutics Ltd (ASX: KZA) share price that’s crashing heavily today. After opening at 35 cents for the day, shares in the oncology-focused drug development company are continuing to freefall....

Motley Fool KZA 2 weeks ago
10 at 10: These ASX stocks are starting August with big gains

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead KZA 2 weeks ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead KZA 3 weeks ago
KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER

SYDNEY, July 12, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of fou...

FNArena KZA 1 month ago
‘World-leading’ brain cancer experts headline Kazia Therapeutics’ new scientific advisory board

Kazia Therapeutics (ASX: KZA) has launched a new scientific advisory board (SAB) consisting of “world-leading experts” in developing therapies for brain cancer. Sydney-based oncology-focused Kazia will lean on SAB’s guidance in progressing...

SmallCaps KZA 1 month ago
Evening Report: 6 July, 2022

ShareCafeEvening Report: 6 July, 2022 by Melissa Darmawan   Australia’s trade surplus hit a record high in May, driven by higher prices of coal, while imports suggested consumer demand is strong as the country continues to open. The surplu...

ShareCafe KZA 1 month ago
Lunch Report: 7 July, 2022

ShareCafeLunch Report: 7 July, 2022 by Melissa Darmawan   Australian stocks have rebounded, helped by Chalice Mining’s latest discovery, which has helped to lift the material sector. Gains in consumer staples and discretionary stocks have o...

ShareCafe KZA 1 month ago
Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

07 Jul 2022 - A snapshot of the stocks on the move, featuring Elsight (ASX:ELS), Kazia Therapeutics (ASX:KZA), and Chalice Mining (ASX:CHN).

FNN KZA 1 month ago
Kazia Therapeutics awarded US FDA rare drug designation for paxalisib in childhood brain cancer

Kazia Therapeutics’ (ASX: KZA) lead drug candidate paxalisib has been awarded rare paediatric disease designation (RPDD) for the treatment of a highly-aggressive childhood brain cancer known as atypical rhabdoid teratoid tumour (AT/RT). The...

SmallCaps KZA 1 month ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead KZA 1 month ago
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pedi...

FNArena KZA 1 month ago
Kazia Therapeutics reports good half-year progress despite market challenges

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies. A Phase I study of...

SmallCaps KZA 1 month ago
New orphan drug designation for Kazia Therapeutics' paxalisib

Kazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designation to its paxalisib for the treatment of atypical rhabdoid/teratoid tumours.

BiotechDispatch KZA 1 month ago
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, June 17, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan D...

FNArena KZA 1 month ago
US FDA awards Kazia Therapeutics (ASX:KZA) Orphan Drug Designation for brain cancer treatment

The US FDA has awarded Kazia Therapeutics (KZA) Orphan Drug Designation (ODD) for its paxalisib drug to treat a rare type of childhood brain cancer The designation is for paxalisib to treat atypical rhabdoid/teratoid tumours which is a rar...

themarketherald.com.au KZA 1 month ago
Why Kazia (ASX: KZA) shares are trading in green today

Highlights Kazia Therapeutics’ lead drug candidate, Paxalisib, secures ODD from the FDA for the treatment of a kind of brain cancer. Kazia will save over US$3 million in fees related to a future regulatory filing in atypical rhabdoid/t...

Kalkine Media KZA 1 month ago
ASX Health Stocks: Kazia Therapeutics gets crucial designation status from the US FDA

Kazia gets designation approval from US FDA Lumos signs contract to make at-home screening test product Trajan acquires US-based company, in trading halt Oncology company Kazia Therapeutics (ASX:KZA) says its lead drug paxalisib has been...

Stockhead KZA 1 month ago
Kazia Therapeutics collars US FDA orphan drug designation for paxalisib in a highly aggressive childhood brain cancer

Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive childhood brain cancer. The ODD is specif...

SmallCaps KZA 1 month ago
Evening Report: 14 June, 2022

ShareCafeEvening Report: 14 June, 2022 by Paul Sanger   The Australian sharemarket has suffered its worst losses in over two years, obliterating $82bn of market capitalisation off the ASX 200. At the closing bell, the S&P/ASX 200 plunge...

ShareCafe KZA 2 months ago
Kazia Therapeutics presents ‘positive data’ on paxalisib in childhood brain cancers

“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two presentations this week at the 20th Internat...

SmallCaps KZA 2 months ago
Stocks of the Hour: Kazia Therapeutics, Westgold Resources & Lake Resources

14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold Resources (ASX:WGX) & Lake Resources (ASX:LKE).

FNN KZA 2 months ago
Kazia Therapeutics (ASX:KZA) new data presented for Paxalisib

Kazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer The data has been presented in two poster presentations at the International Symposium on Pe...

themarketherald.com.au KZA 2 months ago
POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

SYDNEY, June 13, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms...

FNArena KZA 2 months ago
Kazia Therapeutics expands paxalisib study to include secondary brain tumours from breast cancer

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer. The genomically-guided study, led by the US-b...

SmallCaps KZA 2 months ago
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT

SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metasta...

FNArena KZA 2 months ago
Queuing at the ATM: ASX small caps discover a handy source of funding

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

ShareCafe KZA 2 months ago
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

SYDNEY, June 3, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patien...

FNArena KZA 2 months ago
Kazia Therapeutics adds recruitment sites to paxalisib arm of global glioblastoma study

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe. GBM AGILE is a global, academic-led study designed to ident...

SmallCaps KZA 2 months ago
GBM AGILE OPENS TO PAXALISIB IN EUROPE

SYDNEY, May 31, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment t...

FNArena KZA 2 months ago
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO

SYDNEY, May 23, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferen...

FNArena KZA 2 months ago
KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

SYDNEY, May 17, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks ‘DIPG Awareness Day’ by recognizing the tireless work of global researchers in this d...

FNArena KZA 2 months ago
Sector Watch: Healthcare - M&A fever on the cards?

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

FNN KZA 3 months ago
Bargain Barrel: Buys in the battered ASX biotech sector? Ask Boreham!

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

Stockhead KZA 3 months ago
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead KZA 3 months ago
Kazia Therapeutics (ASX:KZA) sets up ADS equity program with Oppenheimer

Oncology-focused drug development company Kazia Therapeutics (KZA) establishes an “at-the-market” equity program, with Oppenheimer & Co acting as sales agent Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million (...

themarketherald.com.au KZA 3 months ago